- Original Articles
- Open Access
Construction of a Novel Bifunctional Biogenic Amine Receptor by Two Point Mutations of the H2-Histamine Receptor
Molecular Medicine volume 1, pages 280–286 (1995)
H2-histamine receptors mediate a wide range of physiological functions extending from stimulation of gastric acid secretion to induction of human promyelocyte differentiation. We have previously cloned the H2-histamine receptor gene and noted that only three amino acids on the receptor were sufficient to define its specificity and selectivity. Despite only modest overall amino acid homology (34% amino acid identity and 57.5% similarity) between the H2-histamine receptor and the receptor for another monoamine, the β2-adrenergic receptor, there is remarkable similarity at their critical ligand binding sites. We hypothesized that, if the specificity and selectivity of both receptors are invested in just three amino acids, it should be possible to convert one of the receptors into one that recognizes the ligand of the other by simple mutations at only one or two sites.
Material and Methods
We explored the effect of two single mutations in the fifth transmembrane domain of the H2-histamine receptor, which encompasses the sites that determine H2 selectivity. The canine H2 receptor gene was mutated at Asp186 and Gly187 (Asp186 to Ala186 and Gly187 to Ser187) by oligonuceotide directed mutagenesis. The coding region of both the wild-type and mutated H2 receptors was subcloned into the eukaryotic expression vector, CMVneo, and stably transfected into Hepa cells and L cells. The biological activity of histamine and epinephrine on the expressed receptor was examined by measurement of cellular cAMP production and inositol trisphosphate formation.
Hepa cells transfected with the Ala186-Ser187 mutant H2 receptor demonstrated a biphasic rise in cAMP in response to epinephrine with an early phase (ED50 ≈10−11 M) that could be inhibited by both propranolol and cimetidine. Epinephrine also induced IP3 generation in the same cells, a biological response that is characteristic of activation of the wild-type H2 but not of the β-adrenergic receptor. L cells transfected with the Ala186-Ser187 mutant H2 receptor also responded to epinephrine in a cimetidine and propranolol inhibitable manner.
We converted the H2-histamine receptor into a bifunctional one that has characteristics of both histamine and adrenergic receptors by two simple mutations. These results support the hypothesis that ligand specificity is determined by only a few key points on a receptor regardless of the structure of the remainder of the molecule. Our studies have important implications on the design of pharmacological agents targeted for action at physiological receptors.
The availability of genes encoding an increasingly wide array of receptors for regulatory substances has led to insight into the molecular basis of ligand-receptor interactions. Recently, we cloned the H2-histamine receptor gene (1) and noted that only three amino acids on the receptor were sufficient to define the specificity and selectivity of the receptor (2). By extrapolation of these findings, it is conceivable that ligand specificity is determined by only a few key points on a receptor regardless of the structure of the remainder of the molecule. We have previously noted a remarkable similarity between the H2-histamine receptor and the receptor for another monamine, the β2-adrenergic receptor, at their critical ligand binding sites. However, there is otherwise only modest overall amino acid homology (34% amino identity and 57.5% similarity), and, furthermore, there is no evidence to indicate cross-reactivity of histamine at β2-adrenergic receptors or, conversely, catecholamines at H2-histamine receptors. We reasoned that, if our hypothesis that the specificity and selectivity of both receptors are invested in just three amino acids is correct, it should be possible to convert one of the receptors into one that recognizes the ligand of the other by simple mutations at only one or two sites. In the present studies, we provide support for this hypothesis by demonstrating that two amino acid substitutions are sufficient to convert the H2-histamine receptor into a novel bifunctional receptor that has characteristics of both histamine and adrenergic receptors.
For these studies, we took advantage of the fact that key areas of homology between the H2-histamine and β2-adrenergic receptors suggest specific amino acids in the third and fifth transmembrane domains of the receptors that might be important for ligand recognition and binding (Fig. 1). Both receptors contain an aspartic acid in the third transmembrane domain that serves as a counter anion to the cationic amine moiety of histamine and catecholamines (2,3). In the fifth transmembrane domain, β2-adrenergic receptors contain two serine moieties (Ser204 and Ser207) that are thought to serve as points for hydrogen bonding to the hydroxyl groups in the catechol ring (4). The H2-histamine receptor has aspartic acid and threonine residues in a comparable but not identical region of its fifth transmembrane domain (Asp186-Thr190) that are important for binding to the imidazole ring of histamine (2). Thus, there is remarkable similarity in the ligand binding sites for histamine and catecholamines on the H2-histamine and β2-adrenergic receptors, respectively, despite the relative lack of homology in the rest of their structure. In light of this observation, we explored the effect of two simple mutations (Asp186 to Ala186 and Gly187 to Ser187) on the pharmacological characteristic of the H2-histamine receptor. We reasoned that these amino acid substitutions, designed to make the putative ligand binding site of the H2-histamine receptor resemble more closely that of the β2-adrenergic receptor, would convert the H2-histamine receptor into one that recognizes catecholamines.
Mutagenesis and Expression
For our studies, the canine H2-histamine receptor gene was subcloned into the sequencing vector M13 and used as a template for the synthesis of DNA with specific mutations according to the method of Kunkel (5). A polymerase chain reaction (PCR) strategy was used to subclone the coding region of both the wild-type and mutated H2-histamine receptors into the eukaryotic expression vector CMVneo, as previously described (2,6). Hepa cells (derived from a rat hepatoma) and L cells (derived from a mouse fibroblast-like cell) were then transfected with the receptor/CMVneo constructs by calcium phosphate copre-cipitation (7) and clones were selected in media containing the neomycin analogue G-418. The expression of receptor RNA was examined by Northern blot analysis and clones expressing roughly equivalent amounts of receptor RNA were used for further studies.
Intracellular cyclic 3′,5′-adenosine monophosphate (cAMP) accumulation was measured using a cAMP Assay Kit (TRK 432; Amersham, Arlington Heights, IL, U.S.A.). Cells transfected with the receptor genes were grown to confluence in 12-well (2.4 × 1.7 cm) tissue culture plates. The cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Grand Island, NY) containing 4.5 g/100 ml glucose, 10% fetal calf serum, 100 units/ml penicillin and streptomycin, 1 mM sodium pyruvate and 1 mg/ml of geneticin. For assays, this media was removed and cells were washed twice with Earle’s balanced salt solution (EBSS) containing 10 mM HEPES (pH 7.4), 1 mM glutamine, 26.5 mM sodium bicarbonate, and 100 mg/ml bovine serum albumin. An aliquot (0.5 ml) of EBSS was placed into each well along with 5 µl of 2 × 10−2 M isobutylmethylxanthine. Varying concentrations of agonist were added and the cells were incubated for 30 min at 37°C. Ice-cold 30% trichloracetic acid (500 µl/well) was added to stop the reaction and precipitate cellular protein. The cells were scraped and transferred to 16 × 150 mm glass tubes then placed on ice for 30 min. The precipitate was then centrifuged for 10 min at 1,900 × g and the supernatant was ether extracted, lyophilized, and resuspended in 50 mM tris, 2 mM EDTA (pH 7.5). cAMP content was then measured by competitive binding assay according to the assay instructions.
Inositol Phospholipid Assays
Transfected Hepa cells were grown to confluence in 2.4 × 1.7 cm multiwell plates and prelabeled with myo [2-3H] inositol at 37°C for 2 hr, adding LiCl (10 µM) 10 min before completing the preincubation period. Histamine or epinephrine were added for varying time intervals and the water soluble cellular products were extracted and separated by ion exchange chromatography on Dowex-1 resin columns as previously described using 100 mM increments of ammonium formate (8). Inositol monophosphate was eluted with 10 mM formic acid/100 mM ammonium formate/5 mM disodium tetraborate, inositol bisphosphate was eluted with 20 mM formic acid/200 mM ammonium formate/5 mM disodium tetraborate, and inositol trisphosphate (IP3) was eluted with 30 mM formic acid/300 mM ammonium formate/5 mM disodium tetraborate. The fraction containing IP3 consists of a mixture containing the 1,4,5 and the 1,3,4 isomers.
As shown in Fig. 2, epinephrine, the catecholamine used in these studies, dose-dependently stimulated the production of cyclic 3′,5′-adenosine monophosphate (cAMP) in nontransfected Hepa cells. These stimulatory effects, obtained at relatively high concentrations of epinephrine (ED50 = 10−7 M), could be inhibited by propranolol but not cimetidine. Thus, there appears to be a classical β-adrenergic receptor on Hepa cells. After transfection with the wild type H2-histamine receptor gene, the Hepa cells demonstrated a biphasic response to epinephrine. The later phase of the response presumably represented the endogenous β-adrenergic receptors and mirrored the effect observed in nontransfected Hepa cells. In contrast, the initial phase of the cAMP response to catecholamine had a much lower ED50 (<10−11 M) and was inhibited with cimetidine but not propranolol. These data indicate that catecholamines are capable of having a minimal action at the standard H2 receptor, perhaps on the basis of the existing similarity in the structure of the binding sites of H2-histamine and β-adrenergic receptors. Upon transfection with the Ala186-Ser187 mutant H2-histamine receptor, the Hepa cells demonstrated, once again, a biphasic response. However, in this instance, the initial phase was greatly exaggerated and, in contrast to the effect obtained with the wild-type H2-histamine receptor, inhibited with either cimetidine or propranolol. As depicted in Fig. 3, histamine dose-dependently stimulated cAMP formation in Hepa cells transfected with the Ala186-Ser187 mutant H2-histamine receptor with an ED50 (3 × 10−8 M) which is similar to that obtained in Hepa cells transfected with the wild-type receptor (data not shown). It is of note that the stimulatory effect of histamine on Hepa cells transfected with the mutant H2 receptor was inhibited with both cimetidine and propranolol, whereas the effect of this secretagogue on the wild-type H2-receptor was inhibited only by cimetidine (data not shown). These data demonstrate that the mutant H2-Wstamine receptor had the bifunctional properties of H2-histamine and β-adrenergic receptors.
We conducted additional studies to characterize the bifunctional nature of the Ala186-Ser187 mutant H2-histamine receptor using selective agonists and antagonists. As shown in Fig. 4, the cAMP response to epinephrine at a dose of 10−9 M, which is below the threshold of the endogenous Hepa cell β-adrenergic receptor, could be inhibited with propranolol, cimetidine, and diphenhydramine, an H1-histamine receptor antagonist. Similarly, when the stimulatory ligand used was histamine, the same inhibitory pattern was observed with the H2-histamine and β-adrenergic receptor antagonists. The H3-histamine receptor antagonist thioperamide did not inhibit either epinephrine or histamine stimulated cAMP formation. Thus, the mutant receptor responded to both adrenergic and histaminergic stimuli and was inhibited by selective antagonists for either class of ligands. It is of considerable interest that the Ala186-Ser187 mutant confers H1-histamine receptor properties to the H2 receptor. This effect was predicted by our previous studies demonstrating that Asp186 of the H2-histamine receptor defines H2 selectivity but is not an essential element in histamine binding (2).
One feature that differentiates H2-histamine from β-adrenergic receptors is that while both receptors are capable of generating a cellular cAMP response, only the former has been shown simultaneously to induce significant turnover of membrane inositol phospholipids and mobilize intracellular calcium (9). Accordingly, to verify that the catecholamine response that we were observing in the Hepa cells transfected with the Ala186-Ser187 mutant H2-histamine receptor was a result of action at the mutant histamine receptor and not the endogenous catecholamine receptor, we examined the effect of epinephrine on membrane inositol phospholipid turnover as measured by the production of IP3. As shown in Fig. 5, epinephrine (10−5 M) induced IP3 generation in Hepa cells transfected with the Ala186-Ser187 mutant H2-histamine receptor. Only a minimal IP3 response was noted at the 10-sec time point in nontransfected Hepa cells. These data confirm that, despite the presence of an endogenous β-adrenergic receptor, there were selective responses of transfected Hepa cells to epinephrine that could be mediated only via action at a bifunctional histamine receptor.
For further confirmation of the bifunctional nature of the Ala186-Ser187 mutant H2-histamine receptor, we transfected both the wild-type and mutant H2-histamine receptors into a second cell line, the L cell. As depicted in Fig. 6, unlike the Hepa cells, nontransfected L cells demonstrated no cAMP response to epinephrine, indicating that they do not express endogenous adrenergic receptors. In very high concentrations, epinephrine demonstrated some ability to induce cAMP generation via action at the wild-type H2 receptor, although this response was inhibited only with cimetidine and not with propranolol. However, a much more characteristic cAMP response to epinephrine was noted in L cells transfected with the Ala186-Ser187 mutant H2 receptor, and this response was inhibited completely with both propranolol and cimetidine. Histamine also induced a dose-dependent rise in cAMP formation in L cells transfected with the Ala186-Ser187 mutant H2 receptor (Fig. 7) and, as with epinephrine, this effect was inhibited with both propranolol and cimetidine. The maximal stimulatory effect of histamine was less than that seen with the wild-type H2 receptor, but the ED50 was similar in both instances. Nontransfected L cells demonstrated no response to histamine. These findings confirm the bifunctional nature of the receptor that transduces the responses activated by epinephrine and histamine. The relatively broad configuration of the dose response curves shown in Figs. 6 and 7 may result from the actions of epinephrine and histamine at a bifunctional receptor as opposed to a single receptor subtype.
We have demonstrated that two amino acid substitutions are sufficient to convert the H2-histamine receptor into a bifunctional one that has characteristics of both the histamine and adrenergic receptors. Our studies suggest that the ligand specific binding properties of a receptor are determined by a surprisingly limited number of key amino acids in its molecular structure. Although there is broad structural similarity among seven transmembrane G protein-linked receptors, there is relatively low amino acid homology between families of receptors for different classes of agonists. Despite the relatively modest overall structural homology between the H2-histamine and β2-adrenergic receptors, two simple amino acid substitutions are sufficient to convert the former receptor into one that has the ligand recognition characteristics of both. Seemingly minor amino acid changes have been reported previously to have profound effects on the pharmacology of G protein-linked seven transmembrane receptors. For example, the alteration of a single amino acid has been shown to account for the pharmacological differences between the rat and human 5-hydroxytryptamine 1B receptors (10,11) and the canine and human cholecystokinin-B/gastrin receptors (12). Similarly, a point mutation in the α2-adrenergic or 5-hydroxytryptamine 1A receptors changes their affinity for β-adrenergic receptor antagonists (13,14). In other studies the receptors for the tachykinins substance P (NK1 receptor) and neurokinin B (NK3 receptor) have been shown to exhibit alterations in receptor binding affinity to nonpeptide antagonists as a result of changes in only one or two of its amino acid residues (15–17).
Our experiments provide the first demonstration that such minor amino acid changes can result in changes in ligand specificity so major that they can cross the gap between entire families of receptors that have only modest structural homology. These findings have important implications in the design of pharmacological agents that are directed at physiological receptors. It is possible, for example, that so-called specific receptor antagonists or agonists may have crossover effects on other groups of receptors that would not be predicted on the basis of overall structural homology. Moreover, it may be possible to utilize unique agonists or antagonists for targeting ligand delivery to artificially constructed mutant receptors that are transfected into various tissues in the body.
Gantz I, Schaffer M, DelValle J, et al. (1991) Cloning of the H2 histamine receptor. Proc. Natl. Acad. Sci. U.S.A. 88: 429–433.
Gantz I, DelValle J, Wang L-D, et al. (1992) Molecular basis for the interaction of histamine with the histamine H2 receptor. J. Biol. Chem. 267: 20840–20843.
Strader CD, Sigal IS, Register RB, Candelore MR, Rands E, Dixon RAF. (1987) Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc. Natl. Acad. Sci. U.S.A. 84: 4384–4388.
Strader CD, Candelore MR, Hill WS, Sigal IS, Dixon RAF. (1989) Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J. Biol. Chem. 264: 13572–13578.
Kunkel TA, Roberts JD, Zabour RA. (1987) Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 154: 367–382.
Brown NA, Steofko RE, Uhler MD. (1990) Induction of alkaline phosphatase in mouse L cells by overexpression of the catalytic subunit of cAMP-dependent protein kinase. J. Biol. Chem. 265: 13181–13189.
Chen CA, Okayama H. (1988) Calcium phosphate-mediated gene transfer: A highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques 6: 632–638.
Wreggett KA, Irvine RF. (1987) A rapid separation method for inositol phosphates and their isomers. Biochem. J. 245: 655–660.
DelValle J, Wang L-D, Gantz I, Schaffer M, Yamada T. (1992) Characterization of H2 histamine receptor: Linkage to both adenylate cyclase and [Ca2+]i signaling systems. Am. J. Physiol. 263: G967–G972.
Oksenberg D, Marsters SA, O’Dowd BF, et al. (1992) A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature 360: 161–163.
Parker EM, Grisel DA, Iben LG, Shapiro RA. (1993) A single amino acid difference accounts for the pharmacological distinctions between the rat and human 5-hydroxytryptamine1B receptors. J. Neurochem. 60: 380–383.
Beinborn M, Lee Y-M, McBride EW, Quinn SM, Kopin AS. (1993) A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature 362: 348–350.
Suryanarayana S, Daunt DA, Von Zastrow M, Kobilka BK. (1991) A point mutation in the seventh hydrophobic domain of the alpha 2 adrenergic receptor increases its affinity for a family of beta receptor antagonists. J. Biol. Chem. 266: 15488–15492.
Guan X-M, Peroutka SJ, Kobilka BK. (1992) Identification of a single amino acid residue responsible for the binding of a class of beta-adrenergic receptor antagonists to 5-hydroxytryptamine1A receptors. Mol. Pharm. 41: 695–698.
Fong TM, Yu H, Strader CD. (1992) Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96, 345 and RP67580. J. Biol. Chem. 267: 25668–25671.
Sachais BS, Snider RM, Low JA, Krause JE. (1993) Molecular basis for the species selectivity of the substance P antagonist CP-96, 345. J. Biol. Chem. 268: 2319–2323.
Gether U, Johansen TE, Snider RM, Lowe III JA, Nakanishi S, Schwartz TW. (1993) Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist. Nature 362: 345–348.
This work was supported by National Institutes of Health (NIH) Grants RO1DK34306 and RO1DK47434, and funds from the University of Michigan Gastrointestinal Peptide Research Center (NIH Grant P30DK34933). Dr. Gantz is a recipient of a Veterans Administration Research Associate Award. We thank Drs. J. Dixon and M. Uhler for their helpful comments on this manuscript.
About this article
Cite this article
DelValle, J., Gantz, I., Wang, L. et al. Construction of a Novel Bifunctional Biogenic Amine Receptor by Two Point Mutations of the H2-Histamine Receptor. Mol Med 1, 280–286 (1995). https://doi.org/10.1007/BF03401552